Fidaxomicin
(Redirected from Dificid)
Fidaxomicin is a macrolide antibiotic used primarily for the treatment of Clostridioides difficile infection (CDI), a condition that can cause severe diarrhea and colitis. It is known for its narrow spectrum of activity, which targets Clostridioides difficile with minimal impact on the normal gut flora.
Mechanism of Action[edit | edit source]
Fidaxomicin works by inhibiting the bacterial enzyme RNA polymerase, which is essential for transcription and subsequent protein synthesis. This inhibition leads to the death of the bacteria, effectively treating the infection.
Pharmacokinetics[edit | edit source]
Fidaxomicin is minimally absorbed from the gastrointestinal tract, which allows it to act locally in the intestines. This property is beneficial as it reduces the risk of systemic side effects and maintains a high concentration of the drug at the site of infection.
Clinical Use[edit | edit source]
Fidaxomicin is specifically indicated for the treatment of Clostridioides difficile infection in adults. It is often reserved for cases where other treatments, such as metronidazole or vancomycin, have failed or are not suitable.
Side Effects[edit | edit source]
Common side effects of fidaxomicin include nausea, vomiting, and abdominal pain. Serious side effects are rare but can include hypersensitivity reactions.
Comparison with Other Treatments[edit | edit source]
Compared to other antibiotics like metronidazole and vancomycin, fidaxomicin has a lower recurrence rate of Clostridioides difficile infection. This makes it a valuable option in the management of recurrent CDI.
History[edit | edit source]
Fidaxomicin was approved by the Food and Drug Administration (FDA) in 2011 for the treatment of Clostridioides difficile infection. It was developed by Optimer Pharmaceuticals and is marketed under the brand name Dificid.
Research and Development[edit | edit source]
Ongoing research is exploring the use of fidaxomicin in pediatric populations and its potential effectiveness against other bacterial infections.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
-
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD
